Syverson Strege & Co’s BioNTech BNTX Stock Holding History

Syverson Strege & Co’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3	Closed	-$1K	–	325
2021 Q3	$1K	Buy	+3	New	+$953	﹤0.01%	425

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Syverson Strege & Co's BNTX Position: Q4 2021 in Review

Syverson Strege & Co sold out of BioNTech (BNTX) in Q4 2021, closing a stake of 3 shares — an estimated $1K sold.

Syverson Strege & Co first reported a position in BNTX in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 354 funds tracked by Wall St. Rank hold BNTX as of Q4 2021.

Syverson Strege & Co reported no remaining BioNTech position as of Q4 2021 after selling out during the quarter.
Syverson Strege & Co sold 3 BioNTech shares in Q4 2021, an estimated $1K.
Syverson Strege & Co first reported a position in BioNTech in Q3 2021 and held it in 1 quarter.
Syverson Strege & Co's BioNTech position peaked at $1K in Q3 2021.
354 funds tracked by Wall St. Rank held BioNTech as of Q4 2021.

Based on Syverson Strege & Co's 13F filing for Q4 2021, filed 19 Jan 2022.